Title: 

Multiple sclerosis – diagnostic test. 

Protection status: 

Know-how in the process of patent application. 

Subject: 

The test is based on the highly specific response of the immune system of multiple sclerosis patients to the autoantigen myelin proteins. It involves assessing the expansion of a subpopulation of specific lymphocytes from the total peripheral blood mononuclear cell (PBMC) population. Since this type of immune response is characterized by high sensitivity, the proposed test will also have high specificity (low false-positive rate). 

Benefits: 

The test will enable early detection of the disease – multiple sclerosis – so that it can be slowed down at the earliest stage. 

Currently, there is no sensitive, specific and validated laboratory test performed from peripheral blood material to make a definite diagnosis when MS is suspected. 

Stage of work: 

Baseline studies have been performed to confirm the original assumptions. A plan for validating the solution is being prepared, and the process of pricing the next stages of the project has begun. 

Application: 

Diagnostics of neurological and immune-mediated diseases, production of PCR tests. 

Contact: 

@: jaroslaw.kowalewski@umed.lodz.pl, tel.: 797 604 075